That distinction makes prolotherapy an interesting option in musculoskeletal pain care, but it can also lead to claims that go beyond the available evidence. Researchers have proposed that dextrose injections may influence inflammatory signaling, connective-tissue activity, and pain perception. Clinical studies have also reported improvements for some musculoskeletal conditions.
However, the exact mechanism is not fully understood, and improvements in pain or function do not automatically prove that a tendon, ligament, or joint has structurally regenerated.
At ReNova Health, dextrose prolotherapy for joint, tendon, and ligament pain is considered according to the condition being evaluated, the tissues involved, examination findings, treatment history, and each patient’s goals.
What Is Dextrose Prolotherapy?
Prolotherapy—short for proliferative therapy—is an injection-based treatment most commonly performed with a concentrated dextrose solution. Dextrose is a form of glucose. In prolotherapy, it is used as a local stimulus rather than as a medication that directly blocks pain.
Depending on the clinical problem, the solution may be placed into or around a joint, tendon, ligament, fascia, or another musculoskeletal structure.
The purpose is to influence the local tissue environment and potentially encourage biological activity associated with healing and pain regulation. That does not mean the treatment works through one proven pathway or produces the same response in every tissue.
Prolotherapy protocols also vary considerably. Published studies have used different:
- Dextrose concentrations
- Injection locations
- Treatment schedules
- Additional solution components
- Approaches to imaging guidance
- Comparison treatments and outcome measures
Even studies involving the same condition may not be evaluating an identical treatment. Findings from one protocol therefore cannot automatically be applied to every form of prolotherapy.
The Proposed Controlled-Irritation Mechanism
The most familiar explanation for prolotherapy is that hypertonic dextrose creates a controlled irritant effect at the injection site.
Researchers propose that this localized response may activate parts of the body’s normal inflammatory and wound-response processes. These processes may influence cellular signaling, connective-tissue healing activity, and the local environment surrounding an injured or painful structure.
This is the basis for describing prolotherapy as an approach intended to support repair rather than simply suppress symptoms.
The mechanism may also involve more than inflammation. Scientific reviews suggest that dextrose could affect sensory nerves and pain-perception pathways. Some clinical improvement may therefore reflect changes in how pain signals are generated or processed rather than structural tissue repair alone.
The relative contribution of these pathways remains uncertain. It may vary according to:
- The concentration of dextrose
- The injection location
- The tissue being treated
- The condition causing the symptoms
- Other treatments used at the same time
It is therefore more accurate to say that prolotherapy is proposed to stimulate a local biological response than to state that it reliably rebuilds damaged tissue.
Pain Relief Is Not the Same as Proven Tissue Regeneration
Pain reduction and improved function matter. They are often the outcomes patients care about most.
Still, these outcomes do not answer every scientific question about what changed within the treated tissue.
Most prolotherapy studies focus on measures such as:
- Pain intensity
- Pain-related function
- Strength or range of motion
- Physical performance
- Quality of life
These measures can show whether patients feel or function better. They do not necessarily demonstrate that a ligament tightened, a tendon regenerated, or damaged cartilage was restored.
Claims about repair therefore require care. Published evidence may support an improvement in pain or function for a particular condition without establishing that prolotherapy regenerated the affected structure.
What the Current Evidence Shows
A 2024 systematic review commissioned through the U.S. Department of Veterans Affairs evaluated 90 studies involving knee osteoarthritis, plantar fasciitis, shoulder pain, lateral elbow tendinopathy, chronic low back pain, and temporomandibular joint disorders.
Most studies were small, treatment protocols varied widely, and nearly half were assessed as having a high, serious, or critical risk of bias.
The review did not support one simple conclusion that prolotherapy either works or does not work. Findings differed according to the condition, injection approach, comparison treatment, follow-up period, and outcome being measured.
Plantar Fasciitis
Plantar fasciitis is one of the conditions with some encouraging evidence.
A 2023 systematic review found low-certainty evidence of medium-term improvements in pain and function compared with saline injections.
Comparisons with active treatments are more complicated. The same review found that corticosteroid injections produced greater short-term pain relief, while dextrose prolotherapy showed potential medium-term benefits compared with saline.
This does not establish prolotherapy as the best treatment for plantar fasciitis. It shows that the timing of outcomes and the treatment used for comparison can significantly affect the conclusion.
Lateral Elbow Tendinopathy
For lateral elbow tendinopathy, sometimes called tennis elbow, low-certainty evidence suggests that dextrose prolotherapy may improve pain-related function compared with saline injections.
Evidence involving strength, physical performance, corticosteroid injections, shockwave therapy, and other active treatments is less certain. Available studies differ in injection technique, follow-up period, and outcome measurement.
The evidence suggests possible benefit for some patients, but it does not establish one consistently superior approach.
Knee Osteoarthritis
Knee osteoarthritis illustrates why prolotherapy evidence can appear contradictory.
The 2024 Veterans Affairs review found that dextrose injected inside the joint probably produced little to no additional benefit over saline injections for several measures of pain-related function, physical performance, and quality of life.
Studies using combined injections inside and around the joint have produced some potentially favorable long-term findings, but the certainty is low or very low.
The distinction matters. “Prolotherapy for knee osteoarthritis” can refer to meaningfully different injection approaches. Combining those protocols into one broad claim can make the evidence appear more conclusive than it is.
Shoulder and Low Back Pain
Evidence for mixed shoulder conditions and chronic low back pain remains uncertain.
For shoulder pain involving bursitis or rotator cuff pathology, some comparisons have shown little or no advantage over saline. Certain physical-performance outcomes favored corticosteroid injections.
For chronic low back pain, the Veterans Affairs review described the evidence as very uncertain compared with saline or corticosteroid injections.
Low back and shoulder pain can also arise from many different structures and diagnoses. Broad symptom labels may conceal clinically important differences among study participants.
Why Prolotherapy Studies Can Reach Different Conclusions
Several recurring limitations make prolotherapy research difficult to interpret.
Protocols Are Not Standardized
Studies vary in dextrose concentration, injection location, number of treatments, spacing between treatments, imaging guidance, and additional substances included in the solution.
Two studies using the word “prolotherapy” may therefore be evaluating different interventions.
Many Studies Are Small
Small trials are more vulnerable to chance findings, imbalances between treatment groups, loss of participants during follow-up, and exaggerated estimates of benefit.
They are also less able to identify uncommon complications.
Injection Effects and Symptom Fluctuation
Injection therapies for musculoskeletal pain can produce substantial placebo effects. The physical effects of an injection procedure may also influence reported symptoms, even when the injected solution does not contain dextrose.
Musculoskeletal symptoms can naturally wax and wane. Rehabilitation, activity changes, and other treatments received alongside an injection may also affect pain and function.
These factors make well-designed comparison trials important when researchers are trying to isolate the effect of dextrose itself.
Safety Reporting Is Incomplete
Temporary soreness and discomfort are commonly discussed in prolotherapy literature. However, the Veterans Affairs review found that adverse events were not evaluated consistently or systematically across many studies.
The absence of frequently reported serious complications is not the same as strong evidence that risks are fully understood. Larger studies with consistent safety monitoring are still needed.
Where ReNova’s Clinical Evaluation Fits
Research summarizes what happened across groups of study participants. It cannot determine whether prolotherapy is appropriate for one individual.
At ReNova Health, the evaluation begins with the source and pattern of the patient’s symptoms rather than assuming that every persistent joint or tendon problem should be treated in the same way.
Relevant considerations may include:
- The suspected condition
- The tissue or structure involved
- Medical and injury history
- Examination findings
- Previous treatments and responses
- Functional limitations
- Treatment goals
Two patients with pain in the same area may have different underlying problems and may receive different recommendations.
ReNova Health evaluates patients through its Ames, Iowa, and Winter Garden, Florida clinic locations. An individualized assessment can help determine whether prolotherapy is a reasonable consideration, whether another approach may fit the clinical findings better, or whether additional evaluation is appropriate.
How Prolotherapy Differs From PRP
Prolotherapy and platelet-rich plasma are both injection-based approaches, but they are not interchangeable.
Prolotherapy typically uses a dextrose solution intended to provoke a localized response. PRP therapy uses a concentrated preparation of platelets obtained from the patient’s own blood.
The limited distinction here is that these treatments use different materials and proposed biological strategies. Determining whether either treatment fits a patient’s condition requires an individualized evaluation.
A Balanced Understanding of Prolotherapy
Dextrose prolotherapy has a plausible biological rationale and a heterogeneous clinical research base. Some studies suggest improvements in pain or function for specific conditions, particularly when compared with saline injections.
The evidence is not equally strong across all uses. Findings are mixed for knee osteoarthritis, uncertain for many shoulder and low-back conditions, and often limited by small studies, variable protocols, risk of bias, and incomplete safety reporting.
The most supportable conclusion is measured:
Dextrose prolotherapy may help some patients with certain musculoskeletal conditions, but the exact mechanism remains uncertain, evidence is condition-specific, and a proposed healing response does not guarantee structural tissue repair or a particular clinical outcome.
Key Takeaways
- Dextrose prolotherapy is an injection-based treatment intended to provoke a localized biological response.
- A controlled inflammatory response is one proposed mechanism, but the treatment may also influence pain-signaling pathways.
- Symptom improvement does not automatically prove that damaged tissue regenerated.
- Evidence differs substantially by condition, injection protocol, comparison treatment, and outcome.
- Research is more encouraging for some plantar-fascia and lateral-elbow outcomes than for many shoulder or low-back applications.
- Evidence for knee osteoarthritis remains mixed and depends partly on the injection approach studied.
- Individual evaluation is necessary because similar symptoms can arise from different tissues and clinical problems.
For people living with persistent joint, tendon, or ligament pain, prolotherapy may be worth a careful, evidence-informed discussion. The decision should be based on an individualized assessment—not on the assumption that one proposed mechanism guarantees healing.
Medical Disclaimer
This article is provided for educational purposes only and does not constitute medical advice. Prolotherapy may not be appropriate for every patient or condition. Individual results vary, and no specific outcome is guaranteed. A qualified healthcare professional should evaluate your medical history, symptoms, examination findings, and treatment options before care is recommended.
Works Cited
U.S. Department of Veterans Affairs, Evidence Synthesis Program. (2024). Dextrose prolotherapy for musculoskeletal pain: A systematic review.
Fong, H. P. Y., Zhu, M. T., Rabago, D. P., Reeves, K. D., Chung, V. C. H., & Sit, R. W. S. (2023). Effectiveness of hypertonic dextrose injection (prolotherapy) in plantar fasciopathy: A systematic review and meta-analysis of randomized controlled trials. Archives of Physical Medicine and Rehabilitation, 104(11), 1941–1953.e9.
Reeves, K. D., Sit, R. W. S., & Rabago, D. P. (2016). Dextrose prolotherapy: A narrative review of basic science, clinical research, and best treatment recommendations. Physical Medicine and Rehabilitation Clinics of North America, 27(4), 783–823.